BSX vs. DVA: Boston Scientific vs. DaVita Stock Comparison

Company Profile

Boston Scientific (BSX) and DaVita (DVA) both fall under the Health Care Equipment & Services industry group, but BSX is classified in Health Care Equipment & Supplies while DVA is classified in Health Care Providers & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Boston Scientific (BSX) is heavily traded at around 19.73M shares per day, whereas DaVita (DVA) sees a more moderate 713.76K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

DaVita (DVA) at 96.79% clears its industry range for ROE, a sharper capital-efficiency signal than Boston Scientific (BSX) at 14.12%, which is closer to a typical peer reading.

Boston Scientific (BSX) at 16.62% retains a top-quartile share of revenue as profit, ahead of DaVita (DVA) at 6.49%, which keeps about the industry-typical share.

Both Boston Scientific (BSX) at 19.05% and DaVita (DVA) at 15.46% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Boston Scientific (BSX) at 19.87% and DaVita (DVA) at 6.46% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Boston Scientific (BSX) at 55.20% sits in the top EPS growth quartile, while DaVita (DVA) at -8.29% is closer to the peer norm — faster per-share earnings growth for BSX.

Growth Metrics

Financial Strength

DaVita (DVA) at 1.41 keeps current ratio within its industry’s typical mid-range, while Boston Scientific (BSX) at 1.37 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BSX.

Boston Scientific (BSX) at 0.46 is near its industry mid-range for debt-to-equity ratio, while DaVita (DVA) at 11.90 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither Boston Scientific (BSX) nor DaVita (DVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Boston Scientific (BSX) nor DaVita (DVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Both Boston Scientific (BSX) at 18.04 and DaVita (DVA) at 14.49 sit in the cheaper earnings-multiple quartile for P/E ratio, with the market paying less for a dollar of trailing earnings than it pays for typical peers.

DaVita (DVA) at 0.85 sits in the cheaper P/S ratio quartile while Boston Scientific (BSX) at 2.94 prices around its industry’s middle — DVA costs less per dollar of sales, though read it alongside growth and margins.

DaVita (DVA) reports a negative P/B ratio of -20.52, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Boston Scientific (BSX) reports 2.42, ranking against industry peers normally.

Valuation Metrics